|
시장보고서
상품코드
2091531
전이성 요로상피암 시장 규모, 점유율, 성장 분석 : 치료법별, 진단별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Metastatic Urothelial Carcinoma Market Size, Share, and Growth Analysis, By Treatment Type (Chemotherapy, Immunotherapy), By Diagnosis (Urine Lab Tests, Cystoscopy), By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 전이성 요로상피암 시장 규모는 2024년에 11억 4,000만 달러로 평가되었으며, 2025년 13억 7,000만 달러에서 2033년까지 58억 2,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 19.9%로 성장할 것으로 전망됩니다.
세계 전이성 요로상피암 시장에는 전이된 진행성 방광암의 치료를 목적으로 하는 의약품, 진단제 및 지지요법이 포함됩니다. 이 질환에 수반되는 높은 사망률과 그동안 치료 선택지가 제한적이었던 점 때문에 투자자와 임상의 모두로부터 혁신적인 치료법에 대한 관심이 높아지고 있습니다. 체크포인트 억제제의 도입을 특징으로 하는 면역요법으로의 전환은 치료 접근 방식을 크게 변화시켰습니다. 현재 북미 및 유럽에서는 항체약물접합체(ADC)와 FGFR 억제제의 최근 승인을 배경으로 매출 증가와 연구 파이프라인의 확대가 나타나고 있습니다. 시장의 주요 성장 요인은 분자 프로파일링을 활용하여 표적 치료를 유도하는 정밀 의학의 도입 확대에 있습니다. 이는 환자의 예후를 개선할 뿐만 아니라, 동반진단제에 대한 제약 업계의 투자를 촉진하여 수요와 시장 확대의 선순환을 만들어내고 있습니다.
세계 전이성 요로상피암 시장의 성장요인
전이성 요로상피암의 치료 환경은 면역요법의 발전에 따라 크게 변화하여, 이전에는 치료 선택지가 제한적이었던 환자들에게도 장기적인 치료 효과를 가져다주고 있습니다. 이러한 치료법들의 우수한 안전성 프로파일뿐만 아니라, 다른 치료법과의 병용을 뒷받침하는 근거가 늘어나고 있다는 점이 임상의들의 신뢰를 높이고 있습니다. 종양 전문의들이 체크포인트 억제제를 1차 치료 프로토콜에 점점 더 많이 포함시키면서, 이러한 혁신적인 약물에 대한 수요가 증가하고 있으며, 그 결과 제약사들의 연구 개발 투자가 활발해지고 있습니다. 이러한 호조는 제품 채택 확대, 임상 현장에서의 인지도 제고, 그리고 전 세계 의료 시스템에서 활발히 진행되고 있는 파이프라인 개발을 통해 시장 확대를 촉진하고 있습니다.
세계 전이성 요로상피암 시장의 제약요인
표적 치료에 수반되는 막대한 비용은 전이성 요로상피암 시장에서 큰 장벽이 되고 있습니다. 보험사나 의료 제도가 보상 승인을 위해 요구하는 복잡한 의료경제평가는 환자의 의료 접근 기회를 제한하고 있습니다. 게다가 의료기관의 재정적 부담으로 인해 보험 적용 약품 목록에 등재되는 것이 제한되는 경우가 많아, 임상의들은 잠재적 유효성이 낮은, 더 저렴한 치료 옵션을 선택할 수밖에 없는 상황에 내몰리고 있습니다. 그 결과, 제조업체들은 수요 감소에 직면하게 되었고, 투자 결정이 비용 대비 효과가 더 높은 대안으로 기울어짐에 따라 시장 성장이 제약을 받고, 전반적인 성장 궤도가 저해되고 있습니다. 이러한 과제들은 시장 상황에 지속적인 영향을 미치는 압박 요인으로 작용하고 있습니다.
세계 전이성 요로상피암 시장의 동향
세계 전이성 요로상피암 시장은 면역요법 및 항체약물접합체(ADC)와 같은 혁신적인 치료법으로의 전환을 특징으로 하며, 눈부신 발전을 이루고 있습니다. 임상의들이 다양한 면역 경로를 표적으로 하는 병용 전략을 도입한 1차 치료 알고리즘을 채택함에 따라, 효과적인 치료 방식은 급속히 변화하고 있습니다. 각 제약사는 이에 대응하여 새롭게 나타나는 내성 기전에 대처하기 위해 개발 파이프라인을 가속화하는 한편, 지불 주체와의 협의에서는 실제 임상 성과에 초점을 맞춘 가치 기반 계약을 중시하고 있습니다. 이러한 패러다임의 전환은 새로운 치료법의 적용 대상이 되는 환자층을 확대할 뿐만 아니라, 새로운 시장 기회를 창출하고, 암 의료 생태계 전반에 걸친 지속가능한 성장을 뒷받침하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 전이성 요로상피암 시장 규모 : 치료 유형별
세계의 전이성 요로상피암 시장 규모 : 진단별
세계의 전이성 요로상피암 시장 규모 : 최종사용자별
세계의 전이성 요로상피암 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSMGlobal Metastatic Urothelial Carcinoma Market size was valued at USD 1.14 Billion in 2024 and is poised to grow from USD 1.37 Billion in 2025 to USD 5.82 Billion by 2033, growing at a CAGR of 19.9% during the forecast period (2026-2033).
The global market for metastatic urothelial carcinoma encompasses pharmaceuticals, diagnostics, and supportive care aimed at treating advanced bladder cancer that has metastasized. The high mortality rate associated with this disease and the historically limited treatment options have spurred interest in innovative therapies from both investors and clinicians. The shift towards immunotherapy, marked by the introduction of checkpoint inhibitors, has significantly transformed treatment approaches. Currently, North America and Europe are experiencing revenue growth and expanding research pipelines, driven by recent approvals of antibody-drug conjugates and FGFR inhibitors. Key market growth is fueled by increasing adoption of precision medicine, utilizing molecular profiling to guide targeted therapy. This not only improves patient outcomes but also encourages pharmaceutical investments in companion diagnostics, creating a cycle of demand and market expansion.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Metastatic Urothelial Carcinoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Metastatic Urothelial Carcinoma Market Segments Analysis
Global metastatic urothelial carcinoma market is segmented by treatment type, diagnosis, end user and region. Based on treatment type, the market is segmented into chemotherapy, immunotherapy, targeted therapy, radiation therapy and intravesical therapy. Based on diagnosis, the market is segmented into urine lab tests, cystoscopy, biopsy and intravenous pyelogram. Based on end user, the market is segmented into hospitals, oncology clinics and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Metastatic Urothelial Carcinoma Market
The landscape of treatment for metastatic urothelial carcinoma has been significantly transformed by advancements in immunotherapy, offering long-lasting responses for patients who previously faced limited therapeutic choices. The favorable safety profiles of these treatments, coupled with growing evidence supporting their use in combination with other therapies, are bolstering clinicians' confidence. As oncologists increasingly incorporate checkpoint inhibitors into first-line treatment protocols, there is a rising demand for these innovative agents, leading to heightened pharmaceutical investment in research and development. This positive momentum is fostering market expansion through greater product adoption, heightened clinical awareness, and active pipeline development observed across global health systems.
Restraints in the Global Metastatic Urothelial Carcinoma Market
The significant expense associated with targeted therapies presents a substantial obstacle in the metastatic urothelial carcinoma market. The intricate health economic evaluations demanded by payers and health systems for reimbursement approvals restrict patient accessibility. Additionally, the financial burden on institutions often limits formulary inclusion, compelling clinicians to resort to less expensive, albeit potentially less effective, treatment options. Consequently, this results in constrained market growth as manufacturers face diminished demand, making investment decisions lean toward more cost-efficient alternatives, thereby impeding the overall growth trajectory. These challenges represent persistent pressures affecting the market landscape.
Market Trends of the Global Metastatic Urothelial Carcinoma Market
The Global Metastatic Urothelial Carcinoma market is experiencing significant evolution, characterized by the shift towards innovative treatment modalities such as immunotherapy and antibody-drug conjugates. As clinicians adopt first-line treatment algorithms that incorporate combination strategies targeting diverse immune pathways, the landscape of effective care is rapidly transforming. Pharmaceutical companies are responding by accelerating their development pipelines to address emerging resistance mechanisms, emphasizing value-based contracts in discussions with payers that focus on real-world outcomes. This paradigm shift not only enhances patient eligibility for novel therapies but also creates new market opportunities, propelling sustained growth across the oncology ecosystem.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Metastatic Urothelial Carcinoma Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Chemotherapy
- Platinum-Based Chemotherapy
- Gemcitabine-Based Chemotherapy
- Immunotherapy
- PD-1/PD-L1 Inhibitors
- CTLA-4 Inhibitors
- Combination Immunotherapies
- Targeted Therapy
- Antibody-Drug Conjugates (ADC)
- FGFR Inhibitors
- Radiation Therapy
- External Beam Radiation
- Stereotactic Body Radiation
- Intravesical Therapy
Global Metastatic Urothelial Carcinoma Market Size by Diagnosis & CAGR (2026-2033)
- Market Overview
- Urine Lab Tests
- Cystoscopy
- Biopsy
- Intravenous Pyelogram
Global Metastatic Urothelial Carcinoma Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Oncology Clinics
- Research Institutes
Global Metastatic Urothelial Carcinoma Market Size & CAGR (2026-2033)
- North America (Treatment Type, Diagnosis, End User)
- US
- Canada
- Europe (Treatment Type, Diagnosis, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Diagnosis, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Diagnosis, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Diagnosis, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (Janssen)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences Inc. (Seagen)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- EMD Serono (Merck KGaA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exelixis Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zymeworks Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Enfortumab vedotin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genentech Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IOVANCE Biotherapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cohesion Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MSD K.K.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ono Pharmaceutical Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ImClone Systems LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
